Eli Lilly and Company ($LLY) Stock Forecast: Up 5.0% Today

What is Eli Lilly and Company?

Eli Lilly and Company (LLY) is a pharmaceutical company known for its innovative treatments in various therapeutic areas, including diabetes, oncology, and neuroscience. Today, LLY experienced a strong bullish movement in the stock market.

Why is Eli Lilly and Company going up?

LLY stock is up 5.0% on May 28, 2026 14:36

• CVS Caremark's decision to reinstate coverage for Eli Lilly's weight-loss drug, Zepbound, effective October 1, has significantly impacted LLY's market performance positively.
• The positive outlook from a research firm, maintaining an Outperform rating and a high price target for LLY, based on strong late-stage Phase 3 data for its obesity drug, retatrutide, has further fueled investor confidence in the company's future prospects.
• Eli Lilly's strategic acquisition of Engage Biologics and the integration of its non-viral DNA delivery technology into Lilly’s genetic medicine and therapeutic delivery systems have showcased the company's commitment to innovation and growth in the pharmaceutical industry.
• The decision by a health company to restore access to Zepbound for over 10 million US patients after Eli Lilly agreed to lower the drug's price demonstrates how pricing strategies and market access can directly influence a company's stock performance.

LLY Price Chart

LLY Technical Analysis

LLY News

CVS Restores Coverage for Eli Lilly's Zepbound (CVS)

CVS Caremark has reinstated coverage for Eli Lilly's weight-loss drug, Zepbound, effective October 1, and will add Foundayo to its formularies on June 1. This strategic move aims to improve patient access and manage rising prescription costs. CVS Health, despite strong profitability and growth metrics, faces financial challenges and significant insider selling.

https://www.gurufocus.com/news/8888413/cvs-restores-coverage-for-eli-lillys-zepbound-cvs

Why Wolfe Research Remains Bullish on Eli Lilly and Company (LLY) and Its Obesity Pipeline

Wolfe Research has maintained an Outperform rating and a $1,350 price target for Eli Lilly and Company (LLY), citing strong late-stage Phase 3 data for its obesity drug retatrutide. The drug showed significant weight reduction and improved cardiometabolic health indicators, reinforcing LLY's leadership in GLP-1-based obesity treatments. Additionally, Eli Lilly recently acquired Engage Biologics for up to $202 million, aiming to integrate its non-viral DNA delivery technology into Lilly’s genetic medicine and advanced therapeutic delivery systems.

https://www.insidermonkey.com/blog/why-wolfe-research-remains-bullish-on-eli-lilly-and-company-lly-and-its-obesity-pipeline-1770065/

CVS Health reintroduces coverage for Lilly’s Zepbound (CVS:NYSE)

CVS Caremark, the pharmacy benefit manager for CVS Health, has decided to restore coverage for Eli Lilly's weight-loss drug, Zepbound, effective October 1. This update was announced on Thursday as part of changes to its most common commercial formularies.

https://seekingalpha.com/news/4597834-cvs-health-reintroduces-coverage-for-lillys-zepbound

CVS brings back coverage for Lilly's obesity drug Zepbound

CVS Health announced it will re-add Eli Lilly's weight-loss drug Zepbound to some of its drug lists for insurance coverage, effective October 1. This decision comes after its pharmacy benefit management unit, Caremark, had previously dropped Zepbound. The move aims to increase access to GLP-1 weight-loss treatments at a more affordable cost for employers and health plans.

https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/

CVS Returns Zepbound to Drug Plans After Lilly Slashes Price

CVS Health Corp. has reversed its decision to restrict access to Eli Lilly & Co.'s obesity drug, Zepbound, for certain drug plans, restoring access for over 10 million US patients. This reversal occurred after Lilly agreed to lower the price of Zepbound for many health plans. Previously, CVS Caremark had limited Zepbound access due to a pricing deal with Novo Nordisk for their rival drug, Wegovy.

https://www.bloomberg.com/news/articles/2026-05-28/cvs-returns-zepbound-to-drug-plans-after-lilly-slashes-price

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Eli Lilly and Company Price History

30.03.2026 - LLY Stock was up 5.3%

• Eli Lilly's strong performance in the market is supported by robust first-quarter financial results and an increased full-year guidance, reflecting notable growth in revenue and earnings per share.
• A legal development involving the partial dismissal of a lawsuit related to GLP-1 from Empower Pharmacy could have contributed positively to the company's market momentum, potentially safeguarding its market position and intellectual property rights.
• The company's strategic positioning in the growing global GLP-1 market and the recent FDA approval of Foundayo for obesity highlight Eli Lilly's dedication to innovation and market expansion, reinforcing investor confidence in its future prospects.

30.03.2026 - LLY Stock was up 9.7%

• Eli Lilly's stock experienced a strong bullish movement today.
• The partial dismissal of the GLP-1 lawsuit against Empower Pharmacy could have positively impacted investor sentiment, providing some clarity and resolution to the legal proceedings.
• This news may have reassured investors about Eli Lilly's commitment to protecting its intellectual property rights and maintaining the integrity of its product offerings.
• The legal developments could have contributed to a sense of stability and confidence in Eli Lilly's business operations, potentially attracting more investors to the stock.

30.03.2026 - LLY Stock was up 8.9%

• Eli Lilly's recent strong bullish movement could be linked to favorable legal developments regarding a lawsuit against Empower Pharmacy concerning cheaper versions of its GLP-1 weight loss drugs. This news likely boosted investor confidence in the company's ability to protect its market share.
• The positive sentiment in the pharmaceutical sector, exemplified by Merck & Co.'s financial performance and regulatory achievements, may have contributed to Eli Lilly's upward momentum.
• Investor optimism towards companies like Eli Lilly may have been influenced by the excitement surrounding potential treatments for Alzheimer's disease psychosis, such as Bristol Myers Squibb's Cobenfy. The focus on addressing unmet medical needs like Alzheimer's disease could have resonated positively in the market.

01.03.2026 - LLY Stock was up 5.3%

• The bullish movement in LLY stock can be attributed to the announcement of its acquisition of Centessa Pharmaceuticals, focusing on advancing treatments for sleep-wake disorders. This strategic move was likely well-received by investors, leading to positive market performance for LLY.
• The increase in Pfizer's stock price and positive Q4 earnings report may have also contributed to the overall bullish sentiment in the pharmaceutical sector, indirectly impacting LLY's stock performance.
• The quarterly distribution declaration by Direxion Daily LLY Bull 2X Shares could have further boosted investor confidence in LLY, signaling potential returns for shareholders.
• The investigation into the sale of Centessa Pharmaceuticals by Kahn Swick & Foti, LLC may have caused some uncertainty in the market, but the overall market reaction seems to have focused more on the growth prospects of LLY through the acquisition.

18.02.2026 - LLY Stock was down 5.6%

• Positive Phase 2 results reported by a competitor in oncology and immunology may have overshadowed Eli Lilly's performance, leading investors to shift their focus towards the competitor's promising pipeline.
• Mosaic's strategic move into rare earths extraction could have diverted investor attention away from traditional pharmaceutical stocks like Eli Lilly, impacting its stock price negatively.
• Livforsakringsbolaget Skandia Omsesidigt's decision to reduce its stake in Eli Lilly could have signaled concerns about the company's future growth prospects, contributing to the bearish movement.
• Overall, the combination of positive developments in other companies' pipelines and shifting investor sentiment towards different sectors may have influenced the bearish trend in Eli Lilly's stock today.

01.04.2026 - LLY Stock was up 7.7%

• An analyst's reaffirmation of a Buy rating and a target price of $1,281 for Eli Lilly's stock indicates confidence in the company's future performance, contributing to the bullish movement.
• Eli Lilly's Q1 2026 earnings call emphasized significant revenue acceleration and hypergrowth momentum, particularly driven by its incretin drugs Mounjaro and Suven, resulting in raised full-year guidance and a positive outlook from analysts and investors.
• The increase in GLP-1 sales, notably from Zepbound and Mounjaro, in Q1 further enhanced investor confidence, with a strong bullish sentiment seen in options data and Wall Street ratings, suggesting over 30% potential upside.
• Despite facing challenges like pricing pressures and competition, Eli Lilly's strategic focus on new product launches like Foundayo and its overall growth trajectory appear to have resonated positively with the market, fueling the bullish movement in the stock.

17.02.2026 - LLY Stock was down 5.2%

• Despite a recent increase, Eli Lilly's stock has encountered a downward trend, potentially linked to analysts' downgrade, hinting at challenges ahead.
• The launch of Eli Lilly's weight-loss pill, Orforglipron, might not be sufficient to counteract concerns arising from the downgrade.
• Positive results from Pfizer on their advanced CDK4 inhibitor, Atirmociclib, could have diverted investor attention to Pfizer's promising pipeline, impacting Eli Lilly's stock negatively.
• Investors could be reassessing Eli Lilly's competitive position in the pharmaceutical sector, especially compared to companies like Pfizer, with robust drug candidates like Atirmociclib.

17.02.2026 - LLY Stock was down 5.7%

• Eli Lilly's stock faced a bearish movement today following a series of downgrades from analysts, including concerns about valuation and emerging competitors in the oral GLP-1 market.
• Despite a strong run-up in the past year and the anticipation of the launch of its new weight-loss pill, orforglipron, later this year, the stock has been downgraded, indicating potential headwinds ahead.
• The downgrades come at a time when the pharmaceutical industry is seeing advancements from competitors, potentially impacting Eli Lilly's market position and growth prospects.
• The overall sentiment towards Eli Lilly remains mixed, with analysts highlighting both the company's recent positive earnings and the challenges it may face in the near future, leading to the bearish movement in the stock today.

24.03.2026 - LLY Stock was down 5.1%

• Eli Lilly's stock experienced a bearish trend possibly due to market concerns surrounding its upcoming earnings report and the performance of its new oral obesity drug, Foundayo.
• Pfizer's expansion of its obesity pipeline and positive Phase 2b results for its anti-obesity candidate may have intensified competition in the obesity care market, impacting investor sentiment towards Eli Lilly.
• The partnership between Merck and Google Cloud to enhance drug development using AI highlights the increasing importance of technological advancements in the pharmaceutical industry, potentially raising the bar for innovation and competitiveness.
• Regulatory challenges faced by AbbVie with FDA's questions on manufacturing processes for its aesthetic neurotoxin could have contributed to a broader cautious sentiment towards pharmaceutical stocks, including Eli Lilly.

15.03.2026 - LLY Stock was down 5.0%

• LLY's stock took a hit today despite announcing the acquisition of Centessa Pharmaceuticals for $7.8 billion, a move aimed at bolstering its neuroscience pipeline. The market reaction might be due to various factors:
• The rebranding of FCB Health New York to Olixir New York by a leading advertising agency could have raised concerns about potential competition in the healthcare marketing sector, impacting investor sentiment towards LLY.
• The partnership between AC Immune and LLY to advance Alzheimer's therapy, with a substantial upfront payment and milestone potential, might have shifted focus away from LLY's core operations, leading to a bearish trend.
• The spotlight on another company's strong obesity drug pipeline and growth prospects in metabolic diseases could have diverted investor attention from LLY's strategic moves, contributing to the downward movement in its stock price.
• Overall, while LLY's acquisition news was positive for its long-term growth strategy, external market dynamics and developments in the healthcare sector likely influenced the bearish trend observed today.

28.04.2026 - LLY Stock was up 5.0%

• CVS Caremark's decision to reinstate coverage for Eli Lilly's weight-loss drug, Zepbound, effective October 1, has significantly impacted LLY's market performance positively.
• The positive outlook from a research firm, maintaining an Outperform rating and a high price target for LLY, based on strong late-stage Phase 3 data for its obesity drug, retatrutide, has further fueled investor confidence in the company's future prospects.
• Eli Lilly's strategic acquisition of Engage Biologics and the integration of its non-viral DNA delivery technology into Lilly’s genetic medicine and therapeutic delivery systems have showcased the company's commitment to innovation and growth in the pharmaceutical industry.
• The decision by a health company to restore access to Zepbound for over 10 million US patients after Eli Lilly agreed to lower the drug's price demonstrates how pricing strategies and market access can directly influence a company's stock performance.

09.01.2026 - LLY Stock was down 5.2%

• The acquisition of Orna by Eli Lilly for up to $2.4 billion may have stirred concerns among investors about potential risks and uncertainties related to the deal.
• Criticism from the FDA regarding Novo Nordisk's obesity pill advertisement, indirectly affecting competitors like Eli Lilly in the GLP-1 market, could have contributed to a negative sentiment in the sector.
• The market response to Pfizer's Q4 results, despite positive strides in its obesity drug segment, may have led to a broader bearish trend in the pharmaceutical industry, impacting stocks such as Eli Lilly.
• Eli Lilly's strategic shift towards diversification beyond obesity drugs through investments in circular RNA therapies could have triggered uncertainty among investors about the company's future direction and challenges in entering new markets.